MA52545A - Anticorps pour radionucléides chélatés - Google Patents

Anticorps pour radionucléides chélatés

Info

Publication number
MA52545A
MA52545A MA052545A MA52545A MA52545A MA 52545 A MA52545 A MA 52545A MA 052545 A MA052545 A MA 052545A MA 52545 A MA52545 A MA 52545A MA 52545 A MA52545 A MA 52545A
Authority
MA
Morocco
Prior art keywords
radionucleides
chelated
antibodies
chelated radionucleides
Prior art date
Application number
MA052545A
Other languages
English (en)
Other versions
MA52545B1 (fr
Inventor
Felix Bormann
Sebastian Fenn
Guy Georges
Alexander Haas
Christian Klein
Florian Lipsmeier
Daniela Matscheko
Joerg Moelleken
Pablo Umana
Barbara Weiser
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA52545A publication Critical patent/MA52545A/fr
Publication of MA52545B1 publication Critical patent/MA52545B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
MA52545A 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés MA52545B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658468P 2018-04-16 2018-04-16
EP19723014.7A EP3781200B1 (fr) 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés
PCT/EP2019/059856 WO2019201959A1 (fr) 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés

Publications (2)

Publication Number Publication Date
MA52545A true MA52545A (fr) 2021-02-24
MA52545B1 MA52545B1 (fr) 2024-08-30

Family

ID=66476592

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52545A MA52545B1 (fr) 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés

Country Status (31)

Country Link
US (2) US20220389116A1 (fr)
EP (2) EP4406607A3 (fr)
JP (3) JP7475283B2 (fr)
KR (1) KR102884852B1 (fr)
CN (1) CN112261952A (fr)
AR (1) AR115053A1 (fr)
AU (1) AU2019254537B2 (fr)
BR (1) BR112020021061A2 (fr)
CA (1) CA3096338A1 (fr)
CL (1) CL2020002680A1 (fr)
CR (1) CR20200548A (fr)
DK (1) DK3781200T3 (fr)
ES (1) ES2985352T3 (fr)
FI (1) FI3781200T3 (fr)
HR (1) HRP20241013T1 (fr)
HU (1) HUE067622T2 (fr)
IL (1) IL277575B2 (fr)
LT (1) LT3781200T (fr)
MA (1) MA52545B1 (fr)
MX (1) MX2020010954A (fr)
MY (1) MY207044A (fr)
PE (1) PE20210442A1 (fr)
PL (1) PL3781200T3 (fr)
PT (1) PT3781200T (fr)
RS (1) RS65753B1 (fr)
SG (1) SG11202010066TA (fr)
SI (1) SI3781200T1 (fr)
TW (1) TWI874314B (fr)
UA (1) UA130541C2 (fr)
WO (1) WO2019201959A1 (fr)
ZA (1) ZA202006121B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (fr) 2017-07-25 2021-05-05 TrueBinding, Inc. Traitement du cancer par blocage de l'interaction de tim-3 et de son ligand
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
AR119382A1 (es) * 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
IL298921A (en) * 2020-07-10 2023-02-01 Hoffmann La Roche Antibodies that bind to cancer cells and direct radionuclides to said cells
JP2024504931A (ja) 2021-01-12 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体
CN116744981A (zh) * 2021-01-13 2023-09-12 豪夫迈·罗氏有限公司 组合疗法
US20240173442A1 (en) 2021-01-13 2024-05-30 Hoffmann-La Roche Inc. Combination therapy
TW202330592A (zh) 2021-12-15 2023-08-01 美商Ｙ單克隆抗體製藥有限公司 具有經減少之多聚化(MULTIMERISATION)的scFv及抗體
TW202434650A (zh) 2022-11-08 2024-09-01 美商Ｙ單克隆抗體製藥有限公司 雙特異性抗體化合物
WO2025176614A1 (fr) 2024-02-20 2025-08-28 F. Hoffmann-La Roche Ag Nouveaux anticorps de pré-ciblage et leurs utilisations
WO2026041568A1 (fr) 2024-08-20 2026-02-26 F. Hoffmann-La Roche Ag Anticorps se liant à cd3 et dotam
WO2026082710A1 (fr) 2024-10-16 2026-04-23 F. Hoffmann-La Roche Ag Récepteurs recombinants inductibles par de petites molécules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
JP6912379B2 (ja) 2014-12-23 2021-08-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物
KR20170110601A (ko) * 2015-02-05 2017-10-11 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
EP3256164B1 (fr) * 2015-02-09 2020-03-25 Memorial Sloan Kettering Cancer Center Anticorps multi-spécifiques ayant une affinité pour l'antigène a33 humain et le complexe métallique dota
KR20180073561A (ko) * 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
EP3243836A1 (fr) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison à un antigène contenant un trimère d'un ligand de la famille du tnf fusionné en terminaison c
ES3054945T3 (en) 2018-04-16 2026-02-09 Orano Med Mfg Sas Antibodies for chelated radionuclides and clearing agents

Also Published As

Publication number Publication date
EP4406607A3 (fr) 2024-10-16
JP2026062683A (ja) 2026-04-10
JP2021520832A (ja) 2021-08-26
PE20210442A1 (es) 2021-03-08
EP4406607A2 (fr) 2024-07-31
UA130541C2 (uk) 2026-03-18
KR20210005885A (ko) 2021-01-15
PL3781200T3 (pl) 2024-09-16
MA52545B1 (fr) 2024-08-30
AU2019254537B2 (en) 2025-06-19
SG11202010066TA (en) 2020-11-27
MY207044A (en) 2025-01-27
TWI874314B (zh) 2025-03-01
JP2024056687A (ja) 2024-04-23
TW202011987A (zh) 2020-04-01
LT3781200T (lt) 2024-08-12
CA3096338A1 (fr) 2019-10-24
US20220389116A1 (en) 2022-12-08
MX2020010954A (es) 2020-11-09
DK3781200T3 (da) 2024-08-05
ZA202006121B (en) 2025-05-28
PT3781200T (pt) 2024-07-19
BR112020021061A2 (pt) 2021-02-17
CN112261952A (zh) 2021-01-22
AU2019254537A1 (en) 2020-10-29
SI3781200T1 (sl) 2024-09-30
EP3781200B1 (fr) 2024-05-29
CR20200548A (es) 2021-01-20
ES2985352T3 (es) 2024-11-05
EP3781200A1 (fr) 2021-02-24
IL277575B2 (en) 2025-11-01
AR115053A1 (es) 2020-11-25
JP7475283B2 (ja) 2024-04-26
KR102884852B1 (ko) 2025-11-14
RS65753B1 (sr) 2024-08-30
CL2020002680A1 (es) 2021-02-12
HUE067622T2 (hu) 2024-10-28
IL277575B1 (en) 2025-07-01
IL277575A (en) 2020-11-30
FI3781200T3 (fi) 2024-07-31
US20260015436A1 (en) 2026-01-15
HRP20241013T1 (hr) 2024-10-25
WO2019201959A1 (fr) 2019-10-24

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
MA52366A (fr) Anticorps anti-tl1a optimisés
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA52742A (fr) Anticorps bispécifiques dll3-cd3
EP3883970A4 (fr) Anticorps anti-b7-h3
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
MA53905A (fr) Anticorps stabilisant trem2
MA47456A (fr) Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
DK3781200T3 (da) Antistoffer for chelaterede radionuklider
MA46057A (fr) Anticorps anti-ctla4
EP3630078A4 (fr) Agents pour chimio-embolisation
EP3752536A4 (fr) Anticorps anti-her2
EP4081547A4 (fr) Nouveaux anticorps anti-fgfr2b
MA52152A (fr) Anticorps
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
EP3583044A4 (fr) Support pour récipients
EP3831851A4 (fr) Anticorps anti-btla
EP3995582A4 (fr) Anticorps anti-epha4
IL284807A (en) Antibodies specific to human nectin-2
MA43587A (fr) Arnm thérapeutiques codant pour des anticorps anti-ctla-4
EP3518973A4 (fr) Anticorps neutralisants dirigés contre le complexe d'intégrine alpha v béta 8 pour l'immunothérapie
MA55705A (fr) Anticorps bispécifiques
EP4081539A4 (fr) Nouveaux anticorps anti-fgfr2b
EP3852779A4 (fr) Anticorps anti-klrg1